{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_26", "age_group": "upto_20", "agreed": true, "close_date_time": "2021-10-30 17:30:47", "close_timestamp": 1638293447472, "created": "30/11/2021 17:30:46", "department": "Computing", "disability": false, "ease": 5, "environment": "production", "experiment_date_datepicker": "2021-11-30", "gender": "female", "id": "2df4b387-511a-4db8-8792-724f6b2efa7b", "open_date_time": "2021-10-30 17:26:35", "open_timestamp": 1638293195083, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "The results presented by Monash University, have shown that a drug in development, Ivermectin, can prevent the spread/ combat coronavirus in up to approx. 48 hours,", "task_condition": "viz", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "under_graduate_year_1", "time_taken_in_seconds": 252389, "what": "The Ivermectin drug can kill COVID-19 within 48 hours", "when_happened": "few_years_ago", "where_location": "Monash University", "who": "Dr Kylie Wagstaff-6", "why": "There is a drug that can prevent the seriousness of Coronavirus. "}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_26", "age_group": "upto_20", "agreed": true, "close_date_time": "2021-10-30 17:18:55", "close_timestamp": 1638292735998, "created": "30/11/2021 17:18:56", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-30", "gender": "female", "id": "c9976c1f-8d66-4fe3-94bd-dcc9a35c908b", "open_date_time": "2021-10-30 17:2:0", "open_timestamp": 1638291720724, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "In summary, The COVID-19 vaccine, NVX-CoV2373 developed by Novavax is successful, despite the decreasing number of people taking it in the US and as a result, the first dose vaccines will be given to countries with a more urgent demand for the supply of 1st does vaccines. There are very few cases associated with the Delta Variant, but the Phase IIb trial in South Africa showed 48% efficacy against Beta while a Phase III trial in the UK indicated 86% efficacy for Alpha. It has shown that the virus is still important in protecting against coronavirus and the company a COVAX  with its partners, Serum Institute of India and GAVI, Will produce vaccines and give them to countries that have a higher demand than in the US", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "under_graduate_year_1", "time_taken_in_seconds": 1015274, "what": "It was about the effectiveness of the  COVID-19 vaccine, NVX-CoV2373 and how even though it was effective, they had more supply then demand. Also taking about the  trials against the Delta variant and the effectiveness in South African version verses Uk version. ", "when_happened": "few_month_ago", "where_location": "US, Mexico, UK, South Africa", "who": "Novavax, US, Mexico, UK, South Africa, Nancy Jaser", "why": "It show the problems assocaiated with the getting people to take the vaccine, why people are still catching the Virus and the battle against the varients. "}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_26", "age_group": "upto_20", "agreed": true, "close_date_time": "2021-10-30 17:35:39", "close_timestamp": 1638293739285, "created": "30/11/2021 17:35:38", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-30", "gender": "female", "id": "38face8c-786c-4e58-ae7a-ec79dd11ca02", "open_date_time": "2021-10-30 17:30:57", "open_timestamp": 1638293457529, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Australian GPs are trying to encourage the Government to get people to prescribe ivermectin triple therapy to fight COVID-19.", "task_condition": "viz", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "under_graduate_year_1", "time_taken_in_seconds": 281756, "what": "Australian GPs urged to prescribe ivermectin triple therapy to combatCOVID-19", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Goverment ", "why": "It tells people that the drug is effective and therfore should be taken advantage of. "}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_26", "age_group": "upto_20", "agreed": true, "close_date_time": "2021-10-30 17:26:0", "close_timestamp": 1638293160529, "created": "30/11/2021 17:26:01", "department": "Computing", "disability": false, "ease": 5, "environment": "production", "experiment_date_datepicker": "2021-11-30", "gender": "female", "id": "25563a08-11b2-441a-8287-b13ca69e98c3", "open_date_time": "2021-10-30 17:19:9", "open_timestamp": 1638292749975, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "Japan's Ministry of Health Labor and Welfare (MHLW) has approved Ronapreve provided Swiss pharma giant Roche (ROG: SIX) and secured of use in 2021. In the clinical trials for this, the drug has reduced hospitalization or death by 70% and symptom duration by four days, as well as a Phase I clinical study, examining the safety, tolerability and pharmacokinetics in Japanese people.Outside Japan, the antibody combination has been authorized for emergency use or temporary pandemic use in additional territories and regions, including in the European Union, USA, India, Switzerland and Canada.", "task_condition": "text", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "under_graduate_year_1", "time_taken_in_seconds": 410554, "what": "Japan being the first country to formally authorize the use of Ronapreve to Covid-19 Patients", "when_happened": "few_years_ago", "where_location": "Japan", "who": "ROG: SIX, Chugai Pharmaceutical, Ronapreve", "why": "It show the process of the first country "}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_26", "age_group": "upto_20", "agreed": true, "close_date_time": "2021-10-30 17:45:29", "close_timestamp": 1638294329588, "created": "30/11/2021 17:45:30", "department": "Computing", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-30", "gender": "female", "id": "6dda7ab2-5bf0-4994-901b-ee170c75efdd", "open_date_time": "2021-10-30 17:35:49", "open_timestamp": 1638293749067, "summary": "The Pfizer vaccine has been distributed to prevent the spread of coronavirus. On the 25th of April 2021, Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) approved the use of Myfembree, which is a daily treatment for heavy menstrual bleeding associated with uterine fibroids. It has allowed a better quality of life for individuals in the US, affecting millions of women a year.\r\n\r\nIN the same month, Pfizer/BioNTech COVID-19 vaccine shelf-life extended to 31 days, proved by new storage conditions. It was the first COVID-19 vaccine to be approved by the UK regulator in December last year, must be stored at ultra-low temperatures until use. The changes, that extend the shelf-life once thawed, are therefore expected to make storage easier and possible for a wider range of health facilities.", "task_condition": "text", "task_key": "pfizer", "task_level": "under_graduate_year_1", "time_taken_in_seconds": 580521}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_26", "age_group": "upto_20", "agreed": true, "close_date_time": "2021-10-30 17:54:20", "close_timestamp": 1638294860298, "created": "30/11/2021 17:54:21", "department": "Computing", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-11-30", "gender": "female", "id": "7c3864c2-752c-45f3-af37-6ab765de671b", "open_date_time": "2021-10-30 17:45:46", "open_timestamp": 1638294346312, "summary": "UK-based drugmaker AstraZeneca (LSE: AZN) has been doing research on coronavirus vaccine but also have work on oncology, provided by the research done by the company. The company has presented data from more than 100 abstracts, including four abstracts selected as late-breakers, 12 oral presentations and one plenary presentation. The executive vice president for oncology Dave Fredrickson has put focus on \u00e2\u0080\u009cstrengthening our leading portfolio in lung and breast cancers as well as haematology.\u00e2\u0080\u009d \r\n\r\nAdditionally, there is new data for Lynparza (olaparib) and Imfinzi (durvalumab), as well as for Calquence (acalabrutinib).", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "under_graduate_year_1", "time_taken_in_seconds": 513986}}}